Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity

A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal v...

Full description

Saved in:
Bibliographic Details
Published in:npj vaccines 2024-08, Vol.9 (1), p.149-15
Main Authors: Hernandez-Franco, Juan F., Jan, Imran M., Elzey, Bennett D., HogenEsch, Harm
Format: Article
Language:English
Subjects:
631/250/590/2291
631/67/2195
Adjuvants
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer vaccines
Cytotoxicity
Immunity (Disease)
Immunotherapy
Infectious Diseases
Kinases
Lymphocytes
Lymphoma
Medical Microbiology
Medical research
Melanoma
Nanoparticles
Proteins
Public Health
Tumors
Vaccine
Vaccines
Virology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A critical aspect of cancer vaccine development is the formulation with effective adjuvants. This study evaluated whether combining a cationic plant-derived nanoparticle adjuvant (Nano-11) with the clinically tested STING agonist ADU-S100 (MIW815) could stimulate anticancer immunity by intradermal vaccination. Nano-11 combined with ADU-S100 (NanoST) synergistically activated antigen-presenting cells, facilitating protein antigen cross-presentation in vitro and in vivo. Intradermal vaccination using ovalbumin (OVA) as a tumor antigen and combined with Nano-11 or NanoST prevented the development of murine B16-OVA melanoma and E.G7-OVA lymphoma tumors. The antitumor immunity was abolished by CD8 + T cell depletion but not by CD4 + T cell depletion. Therapeutic vaccination with NanoST increased mouse survival by inhibiting B16-OVA tumor growth, and this effect was further enhanced by PD-1 checkpoint blockade. Our study provides a strong rationale for developing NanoST as an adjuvant for intradermal vaccination and next-generation preventative and therapeutic cancer vaccines by STING-targeted activation.
ISSN:2059-0105
2059-0105
DOI:10.1038/s41541-024-00943-8